Coya Therapeutics, Inc. (COYA)
NASDAQ: COYA · Real-Time Price · USD
6.40
+0.12 (1.91%)
May 2, 2025, 4:00 PM EDT - Market closed
Coya Therapeutics Employees
Coya Therapeutics had 8 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
8
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$444,258
Profits / Employee
-$1,860,098
Market Cap
107.04M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 8 | 0 | - |
Dec 31, 2023 | 8 | 2 | 33.33% |
Dec 31, 2022 | 6 | 0 | - |
Dec 31, 2021 | 6 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
COYA News
- 7 days ago - Coya Therapeutics: Treg Proof-Of-Concept Continues With Interim FTD Data Release - Seeking Alpha
- 8 days ago - Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia - Business Wire
- 11 days ago - Coya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death) - Business Wire
- 4 weeks ago - Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025 - Business Wire
- 5 weeks ago - Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program - Business Wire
- 6 weeks ago - Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results - Business Wire
- 2 months ago - Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer's Disease Using GLP-1 Agonists and Combinations - Business Wire
- 3 months ago - Coya Therapeutics Now Pivots Toward Phase 2 In ALS And FTD - Seeking Alpha